Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug201 | Active Choice Wiki | 0.58 |
| drug1912 | In-Person Default Wiki | 0.58 |
| drug4218 | Video Default Wiki | 0.58 |
Navigate: Correlations HPO
There are 3 clinical trials
This study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of Niclosamide (DWRX2003) following escalating doses of DWRX2003 administered as an intramuscular injection in healthy volunteers.
Description: AE rate, incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)
Measure: Incidence of Treatment-Emergent Adverse Events Time: follow-up 48 days after dosingDescription: Maximum measured plasma concentration over the time span specified
Measure: pharmacokinetic changes of niclosamide from baseline in each dose group: Cmax Time: follow-up 48 days after dosingDescription: Time of the maximum measured plasma concentration
Measure: pharmacokinetic changes of niclosamide from baseline in each dose group: Tmax Time: follow-up 48 days after dosingDescription: Change in C reactive protein levels
Measure: pharmcodynamic analysis of niclosamide from baseline in each dose group and time point: CRP Time: on Day 3, 7, 10 and 14This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients.
Description: Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)
Measure: Incidence of Treatment-Emergent Adverse Events Time: follow-up 42 days after dosingThis study is designed to assess the safety, tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) in healthy volunteers.
Description: Incidence, severity and causality of adverse events (AEs) and serious adverse events (SAEs)
Measure: Incidence of Treatment-Emergent Adverse Events Time: follow-up 35 days after dosingDescription: Measured through Maximum (peak) plasma drug concentration (Cmax)
Measure: To assess PK parameters of niclosamide injectable (DWRX2003) through Cmax Time: at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28Description: Time to reach Cmax following IP administration (tmax)
Measure: To assess PK parameters of niclosamide injectable (DWRX2003) through tmax Time: at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28Description: Area under the curve from zero to time of last measurable concentration (AUC0-last)
Measure: To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-last Time: at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28Description: Area under the curve from zero to infinity (AUC0-∞)
Measure: To assess PK parameters of niclosamide injectable (DWRX2003) through AUC0-∞ Time: at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28Description: Elimination half-life (t1/2)
Measure: To assess PK parameters of niclosamide injectable (DWRX2003) through t1/2 Time: at Day 1, 2, 3, 5, 7, 10, 14, 21 and 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports